Current read
Proof of concept from 0 study records, 113 active source records, 38 rapid briefs, and 0 timeline events. Evidence maturity is 0/100, human translation signal is 60/100, and frontier activity is extreme (100/100). Frontier activity means research movement, not settled human proof.
This lane has plausible intervention signals but is not mature human evidence.
Commercial bias penalty: 100/100. Confidence: 32/100. Frontier activity means research movement, not settled human proof.
Why this row matters
Cell therapies, exosomes, tissue repair, transplantation, and regenerative medicine moving from case reports to trials. The map tracks whether this lane is moving from biological plausibility toward outcomes people can responsibly discuss.
Current human translation
Human translation is 25/100 based on human-facing studies, clinical/regulatory sources, claims, and published coverage.
Main approaches being tracked
CAR-T and cell therapy, stem-cell transplantation, exosome and tissue-repair programs.
What would move this row up?
Current bottleneck
evidence maturity
Milestones that would move this row up
Row movement
Mini timeline
Newest graph events across studies, sources, briefs, claims, and timeline records
Open evidence gaps
These gaps are matched from the evidence-gap ledger where possible, with row-level placeholders used when the graph is not yet enriched.
Controlled human trials with durable functional benefit for regenerative interventions.
Controlled human trials with durable functional benefit for regenerative interventions.
Manufacturing, product characterization, and long-term safety follow-up.
Manufacturing, product characterization, and long-term safety follow-up.
Evidence that would change the map
- Raise evidence maturity from 0/100 with better controlled studies or stronger replication.
- Raise human translation from 25/100 with outcomes that matter in people, not only biomarkers or mechanisms.
- Preserve safety discipline with clearer limitations, contraindications, and overclaim boundaries as activity grows.
What not to overclaim
- Do not equate patient stories with broad regeneration proof.
- Do not imply commercial stem-cell or exosome clinics are validated by early research.
Research map
Related studies
Study records matched through topic tags, intervention IDs, source IDs, related content, or row-specific tags.
No structured study records are attached to this row yet.
Useful source library entries
Related briefs
Australia's First Child on EB Gene Therapy Is Walking More After Wound Healing
Jacob Burmeister's EB gene-therapy access story is emotionally strong, but it is based on a local/paywalled patient report plus non-Australian regulatory context. Keep draft until Australian access details are directly confirmed.
Why now
The human story is a strong example of rare-disease access friction, but the Australian-specific claim needs better direct sourcing.
- Overclaim risk
- high
- Primary source
- Trade news
- Published
- Jul 9, 2026
Some Early CAR-T Lymphoma Patients Are 10 Years Out Without Relapse
Penn Medicine reports decade-long follow-up from one of the earliest CAR-T lymphoma trials, with some patients alive without relapse after a single infusion.
Why now
Long-term follow-up turns early CAR-T enthusiasm into a decade-scale remission signal for some patients.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jul 5, 2026
First Child Received Experimental Gene Therapy for Cockayne Syndrome
Riaan Singh Digeorge became the first reported patient to receive experimental AAV9 gene therapy for Cockayne syndrome after a parent-led development effort.
Why now
The first-patient milestone turns an ultra-rare parent-led research program into a live human gene-therapy story.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jul 5, 2026
Teen Became First Pediatric Patient Saved by Deceased-Donor Stem Cells
Riley Children's says 14-year-old Noah Britt became the first pediatric patient in the world successfully treated with a bone marrow transplant using stem cells from a deceased donor.
Why now
A local patient story with world-first pediatric framing gives transplant infrastructure a vivid human face.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jul 5, 2026
World-First HIV-to-HIV Lung Transplant Expanded Donor Access
NYU Langone says Bertrand Nelson received the world's first HIV-positive donor to HIV-positive recipient lung transplant under a research protocol, plus a liver transplant, and is off oxygen after four years.
Why now
A world-first transplant milestone connects patient survival, HIV stigma, organ access, and changing federal transplant policy.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jul 5, 2026
NHS Pilot Turned a Declined Donor Liver Into a Transplant
Royal Free London says the first NHS Assessment and Recovery Centre transplant used machine perfusion and extra testing to reassess a donor liver that had been declined by all UK units.
Why now
A hospital-pilot milestone creates a concrete organ-access story with strong emotional reach: a previously declined organ became a transplant opportunity.
- Overclaim risk
- medium-high
- Primary source
- Official
- Published
- Jul 5, 2026